Immunome, Inc. Overview
Pro stress-test →Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company is advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). With recent Phase 3 positive results and expanding pipeline, Immunome is positioned as a promising oncology-focused biotech targeting multiple cancer indications.
Strategic Profile
Pro stress-test →Immunome is a clinical-stage biotechnology company focused on discovering and developing first-in-class targeted therapies for oncology, primarily using antibody-drug conjugate (ADC) technology, leveraging a proprietary, memory B cell-based discovery engine to identify novel antibodies that treat cancers. The company's strategy is centered on cell-surface-targeting agents and small molecules, with the ultimate goal to develop a targeted oncology platform that can overcome resistance and enable bystander activity.
Competitive Landscape
Pro stress-test →Immunome competes in the targeted oncology and ADC therapeutics space against established biotech and pharma competitors developing cancer therapies. Key competitive differentiators include the company's proprietary memory B cell-based discovery engine, validated Phase 3 clinical data, and multi-asset pipeline focusing on cell-surface-targeting and radiotherapy approaches.
Industry Context
Immunome, Inc. operates in Biopharmaceuticals - Targeted Oncology/Immunotherapy.
Key facts
Founded: 2006 · Headquarters: Bothell, Washington · Market cap: $2.45B